United Therapeutics Corp

UTHR

$191.01

+60.4% (1 year change)

Market Cap

$8.57 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$120.76 - $216.90

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

18.19x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $8.57 Billion
Enterprise Value $7.4 Billion
Dividend Yield $0.00 (0.0%)
1 Year Return +60.4%
52-Week High $216.90
52-Week Low $120.76
Beta 0.54
Outstanding Shares 44.9 Million
Avg 30 Day Volume 362 Thousand

Valuation

P/E Ratio 18.19
PEG 29.74
Earnings per Share $10.26
Price to Sales Ratio 5.46
Price to Book Ratio 2.36
Revenue to Enterprise Value 4.65
EBIT to Enterprise Value 16.67
Total Debt to Enterprise Value 0.11
Debt to Equity 0.22

Profitability

Revenue $1.59 Billion
Gross Profit $1.47 Billion
EBIT $444 Million
Net Income $471 Million
Profit Margin 29.61%
Quarterly Earnings Growth (YoY) +61.2%
Return on Equity 12.94%
Return on Assets 9.72%
Return on Invested Capital 9.79%

Insider trades

No purchases

No sells

No purchases

3,460 shares sold (2 transactions)

No purchases

No sells

No purchases

No sells

Q1 2021 Q2 2021 Q3 2021 Q4 2021

About United Therapeutics Corp

CEO: Martine Rothblatt

Employees: 920

Industry: Pharmaceutical Preparation Manufacturing

United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture and our bioinformatics leadership. We also believe that our determination to be responsible citizens - having a positive impact on patients, the environment and society - will sustain our success in the long term. Through our wholly-owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.

Similar stocks

Lilly(Eli) & Co
Gilead Sciences, Inc.
Teva- Pharmaceutical Industries Ltd. - ADR
Pfizer Inc.
Baxter International Inc.
Cytokinetics Inc
Glaxosmithkline plc - ADR
Cardinal Health, Inc.

News

United Therapeutics (NASDAQ:UTHR) Trading Up 3.7%

United Therapeutics (NASDAQ:UTHR) Trading Up 3.7%

United Therapeutics Co. (NASDAQ:UTHR)s share price was up 3.7% during trading on Wednesday . The stock traded as high as $193.24 and last traded at $193.24. Approximately 607 shares traded hands du...

 Dakota Financial News Dakota Financial News, 3 days ago
Legg Mason Asset Management Japan Co. Ltd. Reduces Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Legg Mason Asset Management Japan Co. Ltd. Reduces Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Legg Mason Asset Management Japan Co. Ltd. reduced its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 8.2% in the 2nd quarter, according to its most recent 13F filing with the Secur...

Transcript Daily Transcript Daily, 4 days ago
United Therapeutics’ (UTHR) Tyvaso DPI NDA Gets CRL From FDA (Revised)

United Therapeutics’ (UTHR) Tyvaso DPI NDA Gets CRL From FDA (Revised)

United Therapeutics UTHR announced that the FDA has issued a complete response letter to its new drug application (“NDA”) for its drug device combination therapy, Tyvaso Dry Powder Inhaler or Tyvas...

FXNews24 FXNews24, 5 days ago